Patents by Inventor Yoshinori Ukai
Yoshinori Ukai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10030071Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.Type: GrantFiled: September 5, 2014Date of Patent: July 24, 2018Assignees: UNIVERSITY OF MIYAZAKI, FUJITA HEALTH UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Kazuhiro Morishita, Kazuko Kaneda, Yoshikazu Kurosawa, Gene Kurosawa, Katsuyuki Mitomo, Katsushi Kouda, Yoshinori Ukai
-
Patent number: 9598496Abstract: An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).Type: GrantFiled: May 7, 2012Date of Patent: March 21, 2017Assignees: PERSEUS PROTEOMICS INC., UNIVERSITY OF MIYAZAKIInventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Patent number: 9593165Abstract: The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.Type: GrantFiled: November 8, 2013Date of Patent: March 14, 2017Assignees: UNIVERSITY OF MIYAZAKI, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Publication number: 20160194400Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.Type: ApplicationFiled: September 5, 2014Publication date: July 7, 2016Applicants: UNIVERSITY OF MIYAZAKI, FUJITA HEALTH UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Kazuhiro MORISHITA, Kazuko KANEDA, Yoshikazu KUROSAWA, Gene KUROSAWA, Katsuyuki MITOMO, Katsushi KOUDA, Yoshinori UKAI
-
Publication number: 20150291697Abstract: The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.Type: ApplicationFiled: November 8, 2013Publication date: October 15, 2015Applicants: PERSEUS PROTEOMICS INC., UNIVERSITY OF MIYAZAKIInventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Publication number: 20140114054Abstract: An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).Type: ApplicationFiled: May 7, 2012Publication date: April 24, 2014Applicants: UNIVERSITY OF MIYAZAKI, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Publication number: 20120046451Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.Type: ApplicationFiled: September 21, 2011Publication date: February 23, 2012Applicants: Institute for Antibodies Co., Ltd.Inventors: Yoshikazu Kurosawa, Yasushi Akahori, Nobuhiro Takahashi, Atsushi Sugioka, Nobuhiro Hayashi, Akihiko Takasaki, Kazuhiro Suzuki, Miwa Morita, Gene Kurosawa, Sari Fujiyama, Susumu Tsutsumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Yoshitaka Iba, Mariko Sumitomo, Masachika Azuma, Yoshinori Ukai, Kazuhiro Morishita
-
Patent number: 8048992Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.Type: GrantFiled: February 22, 2006Date of Patent: November 1, 2011Assignees: Institute for Antibodies Co., Ltd.Inventors: Yoshikazu Kurosawa, Yasushi Akahori, Nobuhiro Takahashi, Atsushi Sugioka, Nobuhiro Hayashi, Akihiko Takasaki, Kazuhiro Suzuki, Miwa Morita, Gene Kurosawa, Sari Fujiyama, Susumu Tsustumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Yoshitaka Iba, Mariko Sumitomo, Masachika Azuma, Yoshinori Ukai, Kazuhiro Morishita
-
Publication number: 20090203538Abstract: It is intended to provide a method whereby a plural number of antibodies against cell surface antigens are quickly classified and to provide a method whereby antigens of the thus classified antibodies are quickly identified. Further, it is intended to provide a method of promoting the utilization of the useful data obtained by the above methods. Furthermore, it is intended to provide an antibody which is effective in treating or diagnosing cancer.Type: ApplicationFiled: January 9, 2009Publication date: August 13, 2009Applicant: Institute for Antibodies Co., Ltd.Inventors: Atsushi Sugioka, Mototaka Sugiura, Yasushi Akahori, Nobuhiro Hayashi, Akihiko Takasaki, Miwa Morita, Gene Kurosawa, Mariko Sumitomo, Susumu Tsutsumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Noriko Satou, Masachika Azuma, Yoshinori Ukai, Kazuhiro Suzuki, Yoshikazu Kurosawa, Miho Tanaka, Mamoru Shiraishi
-
Publication number: 20090053243Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.Type: ApplicationFiled: February 22, 2006Publication date: February 26, 2009Applicant: Institute for Antibodies Co., LtdInventors: Yoshikazu Kurosawa, Yasushi Akahori, Nobuhiro Takahashi, Atsushi Sugioka, Nobuhiro Hayashi, Akihiko Takasaki, Kazuhiro Suzuki, Miwa Morita, Gene Kurosawa, Sari Fujiyama, Susumu Tsustumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Yoshitaka Iba, Mariko Sumitomo, Masachika Azuma, Yoshinori Ukai, Kazuhiro Morishita